BIOSECURE Act could affect half of US biopharmaceutical development
In January 2024, the US Senate and House of Representatives introduced the BIOSECURE Act to prevent US companies that collaborate with "foreign...
Flindr Therapeutics BV secures €20m Series A financing
The Series A financing was led by V-Bio Ventures and an international syndicate that includes Johnson & Johnson Innovation – JJDC, Inc., QBIC...
Forbion closes first Bioeconomy Fund with US$75m
Life Science investor Forbion opens a new sector for its lead partners who were eager to put money into industries within the ESG standards. At...
AmphiStar BV secures €6m to expand production
The infusion of €6m in new capital from ECBF, Qbic III and FFTF will empower AmphiStar to kickstart commercial biosurfactant production in...
Electrochaea sells biomethane reactor to Again A/S
Like German bio-CH4 producer Electrochea GmbH, Danish Again A/S is using CO2-fxing archaea, but to manufacture carbon-negative chemicals such...
Gut bacteria seed autoimmunity-inducers
A unique mechanism, reported by an Irish-French research team underscores an emerging theme in microbiome research: that disruptions to gut bacteria...
Tacalyx' extends seed capital financing
Tacalyx GmbH, the 2019 spin-out from Peter Seeberger's glycan research group, has doubled its seed funding from €7m to to a bit over €14m to advance...